公开(公告)号：US20130289112A1

公开(公告)日：2013-10-31

申请号：US13884558

申请日：2011-03-21

Applicant: Jiang Zheng ,  Xinchuan Zheng ,  Xin Liu ,  Hong Zhou ,  Ning Wang ,  Hongwei Cao ,  Yan Li ,  Yongling Lu ,  Kecen Zhao ,  Jingcheng Yang ,  Yang Yang ,  Yuanfeng Zhu ,  Guo Wei ,  Min Huang

Inventor： Jiang Zheng ,  Xinchuan Zheng ,  Xin Liu ,  Hong Zhou ,  Ning Wang ,  Hongwei Cao ,  Yan Li ,  Yongling Lu ,  Kecen Zhao ,  Jingcheng Yang ,  Yang Yang ,  Yuanfeng Zhu ,  Guo Wei ,  Min Huang

IPC: C07C235/34 ,  C07C55/10 ,  C07C57/145 ,  C07C229/24 ,  C07C59/08 ,  C07C59/255 ,  C07C309/04 ,  C07C309/30 ,  C07C53/10 ,  C07C59/245

CPC classification number: C07C309/04 ,  C07C53/08 ,  C07C53/10 ,  C07C53/122 ,  C07C53/124 ,  C07C55/06 ,  C07C55/08 ,  C07C55/10 ,  C07C55/14 ,  C07C57/145 ,  C07C57/15 ,  C07C57/44 ,  C07C59/08 ,  C07C59/245 ,  C07C59/255 ,  C07C59/265 ,  C07C59/50 ,  C07C63/06 ,  C07C229/24 ,  C07C235/34 ,  C07C309/25 ,  C07C309/30

Abstract: Salts of kukoamine B, their preparation method and their pharmaceutical use in preparation of drugs for preventing and treating sepsis. Experiments indicate that salts of kukoamine B have a good effect on antagonizing the key factors inducing sepsis, and can be used in the preparation of drugs for preventing and treating sepsis. Under the current circumstances of the lack of effective measures for the treatment of sepsis in clinical practice, the medicinal formulations, which comprise the salts of kukoamine B, pharmaceutically acceptable carrier and/or diluent, provide a new approach for the prevention and treatment of sepsis.

Abstract translation: kukoamine B的盐，它们的制备方法及其制备用于预防和治疗败血症药物的药物用途。 实验表明，kukoamine B的盐对拮抗诱导败血症的关键因素具有很好的疗效，可用于制备预防和治疗败血症的药物。 目前在临床实践中缺乏治疗败血症的有效措施的情况下，包含kukoamine B，药学上可接受的载体和/或稀释剂的盐的药物制剂提供了预防和治疗败血症的新方法 。

公开(公告)号：US20060258611A1

公开(公告)日：2006-11-16

申请号：US11452267

申请日：2006-06-14

Applicant: Hsiang-Fu Kung ,  Ming-Liang He ,  Bo-Jiang Zheng ,  Yi Guan ,  Marie Lin ,  Ying Peng

Inventor： Hsiang-Fu Kung ,  Ming-Liang He ,  Bo-Jiang Zheng ,  Yi Guan ,  Marie Lin ,  Ying Peng

IPC: A61K48/00 ,  C07H21/02 ,  C12P21/06 ,  C12N15/86 ,  C07K14/165

CPC classification number: C12N15/1131 ,  A61K39/00 ,  A61K48/005 ,  A61K2039/53 ,  C07K14/005 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2770/20022

Abstract: The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.

公开(公告)号：US20060035869A1

公开(公告)日：2006-02-16

申请号：US11240444

申请日：2005-09-29

Applicant: Bruce Hammock ,  Christophe Morisseau ,  Jiang Zheng ,  Marvin Goodrow ,  Tonya Severson ,  James Sanborn

Inventor： Bruce Hammock ,  Christophe Morisseau ,  Jiang Zheng ,  Marvin Goodrow ,  Tonya Severson ,  James Sanborn

IPC: A61K31/17 ,  A61K31/66

CPC classification number: A61K31/325 ,  A61K31/00 ,  A61K31/336

Abstract: Biologically stable inhibitors of soluble epoxide hydrolases are provided. The inhibitors can be used, for example, to selectively inhibit epoxide hydrolase in therapeutic applications such as treating inflammation, for use in affinity separations of the epoxide hydrolases, and in agricultural applications. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 wherein X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R1-R4 is hydrogen, R2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R1 and R3 are each independently a substituted or unsubstituted alkyl, haloalkyl, cycloalkyl, aryl, acyl, or heterocyclic, or being a metabolite or degradation product thereof.

Abstract translation: 提供了生物稳定的可溶性环氧化物水解酶抑制剂。 抑制剂可用于例如在治疗应用中选择性抑制环氧化物水解酶，例如治疗炎症，用于环氧化物水解酶的亲和分离，以及在农业应用中。 用于实施本发明的一类优选的化合物具有式1所示的结构，其中X和Y各自独立地为氮，氧或硫，X可以进一步为碳，R 1， -R 4是氢，当X是氮时，R 2是氢，但当X是硫或氧时，R 2不是存在的，R 4是氢 当Y为氮时，当Y为硫或氧时不存在，R 1和R 3各自独立地为取代或未取代的烷基，卤代烷基，环烷基，芳基，酰基 ，或杂环，或其代谢产物或降解产物。

公开(公告)号：US20050004063A1

公开(公告)日：2005-01-06

申请号：US10848737

申请日：2004-05-19

Applicant: Hsiang-Fu Kung ,  Ming-Liang He ,  Bo-Jiang Zheng ,  Yi Guan ,  Marie Lin ,  Ying Peng

Inventor： Hsiang-Fu Kung ,  Ming-Liang He ,  Bo-Jiang Zheng ,  Yi Guan ,  Marie Lin ,  Ying Peng

IPC: A61K39/00 ,  A61K48/00 ,  C07K14/165 ,  C12N15/113 ,  C07H21/04 ,  C12Q1/70

CPC classification number: C12N15/1131 ,  A61K39/00 ,  A61K48/005 ,  A61K2039/53 ,  C07K14/005 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2770/20022

Abstract: The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.

Abstract translation: 本发明涉及可用于治疗人类中严重急性呼吸综合征（SARS）的治疗剂。 特别地，本发明涉及可用于抑制hSARS病毒的感染和复制的RNA干扰（RNAi）分子。 优选地，RNAi分子靶向hSARS病毒的复制酶区域或hSARS病毒基因的不同位点的组合。 本发明还包括使用RNAi分子来预防和/或治疗SARS的方法。 还包括包含治疗有效量的RNAi分子的疫苗和试剂盒。

公开(公告)号：US06174695B1

公开(公告)日：2001-01-16

申请号：US09312207

申请日：1999-05-14

Applicant: Bruce D. Hammock ,  Mehran F. Moghaddam ,  Jeffrey M. Cheek ,  Babak Borhan ,  James Fergusson ,  David F. Grant ,  Jessica F. Greene ,  Kazuhiko Matoba ,  Jiang Zheng ,  Marlene F. Sisemore

Inventor： Bruce D. Hammock ,  Mehran F. Moghaddam ,  Jeffrey M. Cheek ,  Babak Borhan ,  James Fergusson ,  David F. Grant ,  Jessica F. Greene ,  Kazuhiko Matoba ,  Jiang Zheng ,  Marlene F. Sisemore

IPC: C12Q134

CPC classification number: C12Q1/34 ,  G01N2500/10

Abstract: The present invention provides methods of treating inflammatory diseases mediated by poly-unsaturated lipid metabolites by inhibiting epoxide hydrolase, methods for assaying or screening the epoxide hydrolase inhibitors for inhibitory specificity and for toxicity, and novel biologically active tetrahydrofuran diols of arachidonic acid, including antibodies thereto.

Abstract translation: 本发明提供了通过抑制环氧化物水解酶来治疗由多不饱和脂质代谢物介导的炎性疾病的方法，用于测定或筛选环氧化物水解酶抑制剂以抑制特异性和毒性的方法，以及花生四烯酸的新型生物活性四氢呋喃二醇，包括其抗体 。

公开(公告)号：US6150415A

公开(公告)日：2000-11-21

申请号：US252148

申请日：1999-02-18

Applicant: Bruce D. Hammock ,  Christophe H. Morisseau ,  Jiang Zheng ,  Marvin H. Goodrow ,  Tonya Severson ,  James Sanborn

Inventor： Bruce D. Hammock ,  Christophe H. Morisseau ,  Jiang Zheng ,  Marvin H. Goodrow ,  Tonya Severson ,  James Sanborn

IPC: C12N9/14 ,  A01N47/10 ,  A01N47/28 ,  A61K31/00 ,  A61K31/155 ,  A61K31/17 ,  A61K31/20 ,  A61K31/336 ,  A61K38/46 ,  A61P11/00 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07C275/06 ,  C07C275/26 ,  C07C333/06 ,  C12N9/99

CPC classification number: A61K31/155 ,  A61K31/00 ,  A61K31/17 ,  A61K31/20 ,  A61K31/27 ,  A61K31/336 ,  A61K31/7088 ,  G01N2500/10

Abstract: Biologically stable inhibitors of soluble epoxide hydrolases are provided. The inhibitors can be used, for example, to selectively inhibit epoxide hydrolase in therapeutic applications such as treating inflammation, for use in affinity separations of the epoxide hydrolases, and in agricultural applications. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 ##STR1## wherein X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R.sub.1 -R.sub.4 is hydrogen, R.sub.2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R.sub.4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R.sub.1 and R.sub.3 are each independently a substituted or unsubstituted alkyl, haloalkyl, cycloalkyl, aryl, acyl, or heterocyclic, or being a metabolite or degradation product thereof.

Abstract translation: 提供了生物稳定的可溶性环氧化物水解酶抑制剂。 抑制剂可用于例如在治疗应用中选择性抑制环氧化物水解酶，例如治疗炎症，用于环氧化物水解酶的亲和分离，以及在农业应用中。 用于实施本发明的优选类化合物具有式1所示的结构，其中X和Y各自独立地为氮，氧或硫，X可以进一步为碳，R 1 -R 4中的至少一个为氢，R 2为氢 当X是氮而X是硫或氧时不存在，当Y是氮时，R4是氢，当Y是硫或氧时不存在，R 1和R 3各自独立地是取代或未取代的烷基，卤代烷基，环烷基，芳基 ，酰基或杂环，或其代谢产物或降解产物。

公开(公告)号：US06103665A

公开(公告)日：2000-08-15

申请号：US94926

申请日：1998-06-15

Applicant: A. Daniel Jones ,  Alyson E. Mitchell ,  Bruce D. Hammock ,  Jiang Zheng

Inventor： A. Daniel Jones ,  Alyson E. Mitchell ,  Bruce D. Hammock ,  Jiang Zheng

IPC: C07D307/58 ,  C07D405/06 ,  C12Q1/48 ,  G01N33/00 ,  A01N43/02 ,  A01N43/08

CPC classification number: C07D405/06 ,  C07D307/58 ,  Y10S977/893 ,  Y10S977/896 ,  Y10S977/915 ,  Y10T436/20

Abstract: This invention relates to novel haloenol lactone compounds. These compounds have the following general structure: ##STR1## in which Ar is an aryl group and Y is a haloenol lactone moiety. The compounds of the invention are useful for the specific measurement of particular isoenzymes of glutathione S-transferase. Measurement of glutathione S-transferase isoenzymes has importance in diagnostic medicine. The compounds of the invention are also useful for treatment of drug resistance in cancer and for preventing herbicide resistance in plants.

Abstract translation: 本发明涉及新的卤烯醇内酯化合物。 这些化合物具有以下一般结构：其中Ar是芳基，Y是卤代烯内酯部分。 本发明的化合物可用于特异性测量谷胱甘肽S-转移酶的特定同工酶。 谷胱甘肽S-转移酶同工酶的测定在诊断医学中具有重要意义。 本发明的化合物还可用于治疗癌症中的耐药性和用于防止植物中的除草剂抗性。

公开(公告)号：US07129223B2

公开(公告)日：2006-10-31

申请号：US10848737

申请日：2004-05-19

Applicant: Hsiang-Fu Kung ,  Ming-Liang He ,  Bo-Jiang Zheng ,  Yi Guan ,  Marie Chia-Mi Lin ,  Ying Peng

Inventor： Hsiang-Fu Kung ,  Ming-Liang He ,  Bo-Jiang Zheng ,  Yi Guan ,  Marie Chia-Mi Lin ,  Ying Peng

IPC: A61K31/7088 ,  C07H21/04 ,  C12N5/10 ,  C12N15/50 ,  C12N15/63

CPC classification number: C12N15/1131 ,  A61K39/00 ,  A61K48/005 ,  A61K2039/53 ,  C07K14/005 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2770/20022

Abstract: The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.

Abstract translation: 本发明涉及可用于治疗人类中严重急性呼吸综合征（SARS）的治疗剂。 特别地，本发明涉及可用于抑制hSARS病毒的感染和复制的RNA干扰（RNAi）分子。 优选地，RNAi分子靶向hSARS病毒的复制酶区域或hSARS病毒基因的不同位点的组合。 本发明还包括使用RNAi分子来预防和/或治疗SARS的方法。 还包括包含治疗有效量的RNAi分子的疫苗和试剂盒。

公开(公告)号：US06495370B1

公开(公告)日：2002-12-17

申请号：US09639392

申请日：2000-08-15

Applicant: A. Daniel Jones ,  Alyson E. Mitchell ,  Bruce D. Hammock ,  Jiang Zheng

Inventor： A. Daniel Jones ,  Alyson E. Mitchell ,  Bruce D. Hammock ,  Jiang Zheng

IPC: G01N3300

CPC classification number: C07D405/06 ,  C07D307/58 ,  Y10S977/893 ,  Y10S977/896 ,  Y10S977/915 ,  Y10T436/20

Abstract: This invention relates to novel haloenol lactone compounds. These compounds have the following general structure: in which Ar is an aryl group and Y is a haloenol lactone moiety. The compounds of the invention are useful for the specific measurement of particular isoenzymes of glutathione S-transferase. Measurement of glutathione S-transferase isoenzymes has importance in diagnostic medicine. The compounds of the invention are also useful for treatment of drug resistance in cancer and for preventing herbicide resistance in plants.

Abstract translation: 本发明涉及新的卤烯醇内酯化合物。 这些化合物具有以下一般结构：其中Ar是芳基，Y是卤代烯内酯部分。本发明的化合物可用于特异性测量谷胱甘肽S-转移酶的特定同工酶。 谷胱甘肽S-转移酶同工酶的测定在诊断医学中具有重要意义。 本发明的化合物还可用于治疗癌症中的耐药性和用于防止植物中的除草剂抗性。

公开(公告)号：US20130189710A1

公开(公告)日：2013-07-25

申请号：US13354341

申请日：2012-01-20

Applicant: Ge Lin ,  Jiang Zheng ,  Na Li

Inventor： Ge Lin ,  Jiang Zheng ,  Na Li

IPC: G01N33/53 ,  G01N33/567 ,  C07K16/44

CPC classification number: C07K16/44 ,  C07K2317/33 ,  G01N33/53 ,  G01N33/5308 ,  G01N33/567

Abstract: An antibody, which specifically recognizes adducts between pyrrole and cellular macromolecules. Such adducts are likely to occur in mammals suffering an incident of pyrrolizidine alkaloid poisoning. The antibody can be produced using a synthetic immunogen conjugated with a pyrrole as a hapten and it can be used, for example in an assay kit and/or by itself, as a novel means for detecting or diagnosing pyrrolizidine alkaloid poisoning both clinics and research laboratories.

Abstract translation: 抗体，其特异性识别吡咯和细胞大分子之间的加合物。 这种加合物很可能发生在遭受吡咯烷酮生物碱中毒事件的哺乳动物中。 可以使用与吡咯缀合的合成免疫原作为半抗原来产生抗体，并且其可以用于例如测定试剂盒和/或其本身，作为用于检测或诊断吡咯烷酮生物碱中毒两种诊所和研究实验室的新手段 。